Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

roblitinib (FGF401)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Everest Medicines, Novartis

Drug class:

FGFR4 inhibitor

Related drugs:

FGFR4 expression	Hepatocellular Cancer	FGFR4 expression	Hepatocellular Cancer	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3
KLB expression	Hepatocellular Cancer	KLB expression	Hepatocellular Cancer	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	FGF401 Sensitive: D – Preclinical FGF401 Sensitive : D	FGF401 Sensitive: D – Preclinical FGF401 Sensitive : D